Molina Healthcare Earnings Call: Growth Wins vs. Strain
Molina Healthcare Inc ((MOH)) has held its Q4 earnings call. Read on for the main highlights of the call.
Valentine's Day Sale - 70% Off
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Molina Healthcare’s latest earnings call painted a cautious but balanced picture, as management juxtaposed robust long-term growth wins with acute near-term earnings and cash flow pressures. Executives stressed that large Medicaid contract victories and a growing embedded earnings base support future value, yet acknowledged that 2025–2026 will be weighed down by higher medical costs, Medicare setbacks, and liquidity strain.
Premium Revenue Growth Remains Solid
Molina reported full-year premium revenue of $43.1 billion, up 11% year over year, underscoring continued top-line expansion despite operational challenges. Fourth-quarter premium revenue reached $10.7 billion, showing that scale is intact even as profitability and trend management have become more difficult.
Embedded Earnings Power and RFP Pipeline Swell
Embedded earnings climbed to more than $11.00 per share from $8.65, including about $4.50 tied to the Florida Children’s Medical Services win, signaling meaningful earnings yet to be realized. Management also highlighted an active request-for-proposal pipeline of roughly $50 billion, suggesting ample runway for further contract-driven growth.
Historic Medicaid Wins Underpin Growth Story
A centerpiece of the call was the historic Florida Children’s Medical Services contract, described as a roughly $6 billion annual run-rate opportunity. Combined with wins and renewals in states such as Wisconsin, plus additions in Georgia and Texas, Molina now has more than $9 billion of new or announced Medicaid premium in the pipeline.
Exceptional RFP Win Rates Support Revenue Durability
Molina emphasized its high RFP success rate, winning around 90% of renewals that protected $14 billion of revenue. The company also achieved an approximately 80% win rate on new contracts, supporting $20 billion of new revenue and reinforcing its competitive positioning in managed Medicaid procurements.
Medicaid Scale and Margin Outperformance
Medicaid remains Molina’s flagship business, accounting for roughly 75% of premium revenue and delivering a full-year pretax margin of 2.8%. The reported Medicaid medical cost ratio was 91.8% for the year, with fourth-quarter adjusted MCR at 92.3%, and management argued its Medicaid margins lead peers by 300–400 basis points.
2026 Guidance Highlights Underlying Earnings Levers
For 2026, the company guided to about $42 billion in premium revenue and adjusted EPS of at least $5, but disclosed underlying EPS nearer $7.50 after backing out known temporary drags. Management pointed to three upside levers: potential moderation in Medicaid trends, off-cycle rate adjustments, and conservative assumptions in Medicare and Marketplace that could prove better than forecast.
Balance Sheet, Capital Markets, and Liquidity
The company harvested roughly $337 million of subsidiary dividends and ended with about $223 million of parent cash, while its risk-based capital ratio stood at approximately 305%, more than 50% above state minimums. Molina also issued $850 million of senior notes due 2031, leaving leverage at 3.7 times trailing EBITDA and debt-to-capital near 49%.
Cost Discipline Keeps G&A in Check
Operational discipline on overhead was a bright spot, with the adjusted G&A ratio at 6.9% in the fourth quarter and 6.5% for the full year. Looking ahead to 2026, management targets about 6.4%, reflecting ongoing cost management and some offsets from implementation spending related to new business.
EPS Miss and Fourth-Quarter Loss Underscore Pressure
Despite revenue growth, Molina delivered full-year adjusted EPS of $11.03, far below its initial $24.50 guidance, with nearly half of the shortfall coming from the Marketplace segment. The fourth quarter was particularly weak, with an adjusted loss per share of $2.75 and earnings roughly $3.00 below expectations, illustrating the severity of recent headwinds.
California Retro Adjustments Hit Q4 Results
Unexpected retroactive Medicaid premium items in California totaled about $135 million, or roughly $2.00 per share, and weighed heavily on the quarter. These items added roughly 160 basis points to fourth-quarter Medicaid MCR and were also conservatively reflected in the 2026 guidance framework.
Medical Cost Trend Spike Weighs on 2025 Margins
Molina raised its 2025 medical cost trend assumption to 7.5% from 4.5%, with around 250 basis points linked to acuity shifts from Medicaid redeterminations. This higher trend materially pressures margins and forces the company to rely more on future rate relief and utilization normalization to restore profitability.
Marketplace Segment Delivers Outsized Damage
The Marketplace business, while only about 10% of premium, drove nearly half of the full-year EPS underperformance, highlighting its disproportionate risk. In the fourth quarter, Marketplace MCR was 99%, with a full-year MCR of 90.6%, reflecting elevated utilization and adverse prior-period claim settlements with providers.
Medicare Struggles and MAPD Exit Decision
Medicare performance was also soft, with elevated utilization in long-term services and supports and high-cost drugs pushing the fourth-quarter MCR to 97.5% and the full-year figure to 92.4%. Slower-than-expected margin recovery in Medicare Advantage prompted Molina to plan an exit from traditional MAPD in 2027, generating about a $1.00 per share headwind to 2026 and implying a negative Medicare pretax margin of roughly -1.7%.
Reduced 2026 EPS Outlook and Known Drags
Reflecting these pressures, 2026 adjusted EPS guidance was cut to at least $5 from a prior outlook near $14, with management detailing specific drags. These include a $1.50 per share hit from Florida CMS startup costs, a $1.00 impact from MAPD underperformance, and additional headwinds of roughly $1.50 combined from higher tax and interest expenses and lower volumes.
Marketplace Contraction and Membership Risk
Molina plans to shrink its Marketplace business, projecting a roughly 50% decline in premium, or about $2.3 billion, and ending 2026 with roughly 220,000 members versus 650,000 today. Management expects effectuation of only around 60% on new members and sees uncertainty around renewals, making membership and margin execution a key risk.
Cash Flow Outflows and Reserve Timing Effects
Operating cash flow for 2025 is expected to be an outflow of about $535 million, driven by Medicaid risk corridor settlements, tax timing, and weaker performance in the second half. Days in claims payable sit around 47, and early reserve builds for new contracts add near-term pressure to the income statement, even as they are intended to support future stability.
Broad-Based Utilization Pressures Built into Outlook
The company cited sustained high utilization across key categories, with pharmacy trend around 13% and top therapeutic classes rising about 35%. Behavioral health prevalence is roughly 20%, with behavioral services trending 18%, while professional visit intensity is up 16% and long-term services and supports continue to rise, all feeding into a 5% core trend assumption for 2026.
Leverage and Covenant Flexibility Tied to Recovery
With leverage at 3.7 times trailing EBITDA and debt-to-capital near 49%, Molina negotiated covenant amendments with its bank syndicate to ensure flexibility. These metrics highlight the company’s sensitivity to the timing of earnings recovery and underline why execution on rate, utilization, and product exits is critical.
Guidance Framed by Caution and Embedded Upside
For 2026, Molina projects about $42 billion in premium revenue and adjusted EPS of at least $5, or roughly $7.50 on an underlying basis after backing out Florida CMS startup costs and MAPD headwinds. The company expects Medicaid premium of $33.4 billion with a 92.9% MCR and 1.2% pretax margin, Medicare premium of $6.6 billion with an MCR of 94% and negative pretax margin, and Marketplace premium of $2.2 billion with improved MCR and modest profitability, while reiterating that each 100-basis-point shift in Medicaid MCR can move EPS by about $5.
Molina’s earnings call left investors weighing sizable long-term growth assets against pronounced short-term pain across earnings, cash flow, and utilization. Management’s message was that disciplined execution on Medicaid, exits from weaker products, and eventual trend moderation could unlock the embedded earnings base, but the path back to higher EPS and lower leverage will likely be gradual and closely watched by the market.
